Pembrolizumab plus axitinib versus sunitinib monotherapy as firstline treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial (vol 21, p1563, 2020)

T Powles; ER Plimack; D Soulières

Pembrolizumab plus axitinib versus sunitinib monotherapy as firstline treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial (vol 21, p1563, 2020)

T Powles
, ER Plimack
, D Soulières

Research output: Contribution to journal › Article › peer-review

Original language	American English
Pages (from-to)	E553-E553
Number of pages	1
Journal	Lancet Oncology
Volume	21
Issue number	12
State	Published - Dec 2020

Fingerprint

Dive into the research topics of 'Pembrolizumab plus axitinib versus sunitinib monotherapy as firstline treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial (vol 21, p1563, 2020)'. Together they form a unique fingerprint.

Cite this

@article{cfaa3f4f01294d1684f02f42528c7f99,

title = "Pembrolizumab plus axitinib versus sunitinib monotherapy as firstline treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial (vol 21, p1563, 2020)",

author = "T Powles and ER Plimack and D Souli{\`e}res",

year = "2020",

month = dec,

language = "American English",

volume = "21",

pages = "E553--E553",

journal = "Lancet Oncology",

issn = "1470-2045",

publisher = "Elsevier Ltd.",

number = "12",

}

Pembrolizumab plus axitinib versus sunitinib monotherapy as firstline treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial (vol 21, p1563, 2020). / Powles, T; Plimack, ER; Soulières, D.
In: Lancet Oncology, Vol. 21, No. 12, 12.2020, p. E553-E553.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Pembrolizumab plus axitinib versus sunitinib monotherapy as firstline treatment of advanced renal cell carcinoma (KEYNOTE-426)

T2 - extended follow-up from a randomised, open-label, phase 3 trial (vol 21, p1563, 2020)

AU - Powles, T

AU - Plimack, ER

AU - Soulières, D

PY - 2020/12

Y1 - 2020/12

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:000599899200016&DestLinkType=FullRecord&DestApp=WOS

M3 - Article

SN - 1470-2045

VL - 21

SP - E553-E553

JO - Lancet Oncology

JF - Lancet Oncology

IS - 12

ER -

Pembrolizumab plus axitinib versus sunitinib monotherapy as firstline treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial (vol 21, p1563, 2020)

Other files and links

Fingerprint

Cite this